Clinical trial NCT04747054: Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Official title: Randomized Trial of Loco-regional Radiotherapy Added to Pembrolizumab Alone or With Chemotherapy Versus Systemic Treatment Alone for Patients With Newly Diagnosed Head and Neck Squamous Cell Carcinoma With Synchronous Metastases
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Squamous Cell Carcinoma of Head and Neck
Keywords: Metastatic
Radiotherapy
pembrolizumab
Squamous Cell Carcinoma
Head and Neck
Carcinoma
Lead sponsor: UNICANCER
Sponsor class: OTHER
Collaborators: name: GORTEC
name: National Cancer Institute, France
First posted: 2021-02-10
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers

Detailed description: Comparative interventional prospective phase 3, randomised, open-label, multicentric trial comparing the combination of radiotherapy and pembrolizumab alone or with chemotherapy to systemic treatment as first line treatment of patients with newly diagnosed head and neck squamous cell carcinoma with synchronous metastases.

Eligibility criteria: Inclusion Criteria:

1. Patient must have signed a written informed consent form prior to any study specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
2. Histologically confirmed squamous cell carcinoma of head and neck (oral cavity, oropharynx, hypopharynx, and larynx) including unknown primary head and neck lymph nodes with distant metastases at presentation (T1-4 N0-3 M1). Histological confirmation is required in case of a single metastatic lesion.
3. Eligible for treatment by pembrolizumab according to the European Marketing Authorization
4. Patient ≥18 years old
5. Performance status: 0-1 (WHO)
6. Combined Positive Score (CPS) ≥1 for primary tumor (as determined per local practice)
7. Subjects must have at least one measurable lesion as per RECIST v1.1 to assess efficacy
8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to randomization:

   a. If randomization is done before treatment start: i. Absolute neutrophil count ≥1.5 × 10⁹/L ii. Platelet ≥100 × 10⁹/L iii. Hemoglobin ≥90 g/L iv. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT), ≤3 × upper limit of normal (ULN), (unless documented liver metastases where ≤5 x ULN is permitted) v. Bilirubin ≤1.5 × ULN. vi. Serum albumin ≥25 g/L vii. Creatinine clearance ≥30 mL/min (calculated per institutional guidelines or by Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formula) viii. Corrected serum calcium of ≤11.5 mg/dL or ≤2.6 mmol/L. b. If randomization if done after treatment start i. Absolute neutrophil count ≥1.0 × 10⁹/L ii. Platelet ≥75 × 10⁹/L iii. Hemoglobin ≥85 g/L
9. Patient must agree to use adequate contraception methods for the duration of the study treatment and up to 4 months after the last dose of pembrolizumab administration
10. Patients must be affiliated to a Social Security System (or equivalent)
11. No disease progression during systemic treatment if the randomization is done after the start of pembrolizumab for the current disease

Exclusion Criteria:

1. Symptomatic central nervous system (CNS) metastases and / or carcinomatous meningitis
2. History of another malignancy within 2 years prior to study inclusion, with the exception of completely resected basal or squamous cell skin cancer, or successfully treated in-situ carcinoma
3. Prior radiotherapy in the head and neck region
4. Any prior or current non-surgical treatment for invasive head and neck cancer. (except for pembrolizumab +/- chemotherapy for the current cancer for a maximum of 6 cycles). This will include but is not limited to: prior tyrosine kinase inhibitors, any monoclonal antibody, chemotherapy, anti-PD-1/PD-L1 and CTLA-4, prior radiotherapy (RT), or use of any investigational agent. Loco-regional recurrent or second primary head and neck cancer after prior surgical treatment alone in the head and neck region could be eligible.
5. Known Acquired Immune Deficiency Syndrome (AIDS)
6. Known currently active infection including hepatitis B or hepatitis C
7. Patient having received live attenuated vaccine within 28 days prior to enrolment
8. Pregnant or breast feeding woman
9. Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized with hormonal substitution, or psoriasis which do not require systemic treatment
10. Active immunodeficiency or ongoing immunosuppressive therapy
11. Active symptomatic interstitial lung disease
12. Significant disease which, in the judgment of the investigator, as a result of the medical interview, physical examinations, or screening investigations would make the patient inappropriate for entry into the trial
13. Any social, personal, medical, geographic and/or psychologic factor(s) that could interfere with the observance of the patient to the protocol and/or the follow-up and/or the signature of the informed consent
14. Prior organ transplantation including allogenic stem-cell transplantation
15. Other severe acute or chronic medical conditions including colitis, pneumonitis, pulmonary fibrosis or psychiatric conditions including active suicidal ideation; or laboratory abnormalities that may increase the risk associated with study participation and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
16. Person deprived of their liberty or under protective custody or guardianship
17. Patient who have taken any investigational medicinal product or have used an investigational device within 30 days prior to study inclusion

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: From randomization to disease progression or death, up to 3 years.
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: From randomization to death from any cause, up to 5 years.
measure: Quality of life questionnaire - Core 30 (QLQ-C30)
timeFrame: At baseline, 4 months, 6 months, 12 months, 18 months, 2 years, 3 years, and 4 years
measure: Quality of Life Questionnaire - Head & Neck Cancer Module (QLQ-H&N35)
timeFrame: At baseline, 4 months, 6 months, 12 months, 18 months, 2 years, 3 years, and 4 years
measure: Objective response rate (ORR)
timeFrame: At 18 weeks and 27 weeks
measure: Loco-regional progression
timeFrame: From randomization to loco-regional progression, up to 5 years.
measure: Distant progression
timeFrame: From randomization to distant progression, up to 5 years.
measure: Progression-free survival 2 (PFS2)
timeFrame: Up to 5 years after randomization.
measure: Incidence of Treatment Adverse Events
timeFrame: Throughout study completion, up to 5 years.
measure: Compliance to treatment
timeFrame: Throughout study treatment, up to 5 years
Other outcomes:
Locations:
city: Avignon
country: France
facility: Institut Sainte Catherine
city: Besançon
country: France
facility: CHU Jean Minjoz
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Bordeaux
country: France
facility: Institut Bergonié
city: Caen
country: France
facility: Centre François Baclesse
city: Carcassonne
country: France
facility: CH Carcassonne
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin
city: Dijon
country: France
facility: Centre Georges François Leclerc
city: Le Havre
country: France
facility: Centre Guillaume le Conquérant
city: Le Mans
country: France
facility: Centre Jean Bernard - Clinique Victor Hugo
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lorient
country: France
facility: Groupe Hospitalier Bretagne Sud
city: Lyon
country: France
facility: Centre Léon Bérard
city: Marseille
country: France
facility: Hopital de la Timone
city: Montbéliard
country: France
facility: Hopital Nord Franche Comté - Site de Mittan
city: Nice
country: France
facility: Centre Antoine Lacassagne
city: Reims
country: France
facility: Institut Jean Godinot
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Saint-Priest-en-Jarez
country: France
facility: CHU de Saint Etienne
city: Strasbourg
country: France
facility: Institut de Cancérologie Strasbourg-Europe
city: Tarbes
country: France
facility: Polyclinique de l'Ormeau
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Valence
country: France
facility: Hopital Privé Drome Ardeche
city: Valence
country: France
facility: CH Valence
city: Vandoeuvre les nancy
country: France
facility: Institut de Cancérologie de Lorraine
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Yungan TAO, Dr
role: PRINCIPAL_INVESTIGATOR
affiliation: Gustace Roussy
name: Caroline EVEN, Dr
role: PRINCIPAL_INVESTIGATOR
References: